High sustained viral response among HCV genotype 3 patients with advanced liver fibrosis: real-world data of HCV elimination program in Georgia

OBJECTIVE: In 2015, Georgia launched HCV elimination program. Initially, patients with advanced liver disease were treated with sofosbuvir-based regimen—the only DAA available for all genotypes. Purpose of the study was assessing real-world data of treatment outcome among patients with HCV GEN3 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Butsashvili, Maia, Gvinjilia, Lia, Kamkamidze, George, Metreveli, David, Dvali, Shorena, Rukhadze, Tamar, Gamkrelidze, Amiran, Nasrullah, Muazzam, Shadaker, Shaun, Morgan, Juliette, Averhoff, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353763/
https://www.ncbi.nlm.nih.gov/pubmed/32653020
http://dx.doi.org/10.1186/s13104-020-05173-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353763/
https://www.ncbi.nlm.nih.gov/pubmed/32653020
http://dx.doi.org/10.1186/s13104-020-05173-4

Ejemplares similares